Dr. Linda Nguyen Joins Babylon Dental Care, Expanding Exceptional Patient Care
BABYLON, NY, UNITED STATES, March 2, 2025 / EINPresswire.com / -- Babylon Dental Care proudly welcomes Dr. Linda Nguyen to its team of dedicated dental professionals. Dr. Nguyen officially joined the practice on January 7, 2025, bringing a wealth of experience, advanced expertise, and a passion for patient-centered care.
Dr. Nguyen earned her Doctor of Dental Surgery (DDS) degree from the University of Maryland after completing her undergraduate studies in Biochemistry at the University of Maryland, College Park. She further honed her skills through a one-year residency at the University of Maryland, where she gained experience in a range of dental procedures, from general and cosmetic dentistry to root canal therapy and extractions.
Her philosophy of care centers on precision, patient education, and a minimally invasive approach. Dr. Nguyen specializes in general and cosmetic dentistry, Invisalign, root canal therapy, extractions, and All-on-X overdentures. She believes in fostering strong patient relationships and ensuring a comfortable, stress-free experience for everyone she treats.
Dr. Nguyen is thrilled to join the talented team at Babylon Dental Care and become a trusted resource for the community's dental needs. 'I look forward to working alongside my colleagues to provide comprehensive, compassionate care that meets each patient's unique needs' says Dr. Nguyen.
Jenn Brown, COO of Babylon Dental Care, expressed excitement about Dr. Nguyen's addition to the team: 'Dr. Nguyen's expertise, dedication, and warm approach to patient care make her a perfect fit for our practice. We are confident that our patients will appreciate her personalized and gentle approach to dentistry.'
About Babylon Dental Care:
Babylon Dental Care has proudly served Babylon and surrounding communities since 1983. With a focus on treating every patient like family, our team is dedicated to providing personalized, comprehensive dental care that enhances health, confidence, and smiles.
www.babylondentalcare.com or call (631) 587-7373.
Babylon Dental Care
+1 516-680-1133
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
9 hours ago
- Associated Press
WILDFIRES: 98% of People in Canada Living with Asthma Say Poor Air Quality Worsens Their Health
7 Practical Steps to Keep Your Asthma Managed This Wildfire Season TORONTO,, ONTARIO, CANADA, June 12, 2025 / / -- As wildfires once again rage across the country, Asthma Canada is urging people living with asthma to take serious precautions. Wildfire smoke contains harmful pollutants, including fine particulate matter that can settle deep in the lungs. For the more than 4.6 million Canadians living with asthma, exposure to smoke can trigger severe symptoms—and, in some cases, lead to fatal asthma attacks. In Asthma Canada's most recent national survey, A Snapshot of Asthma in Canada, over 1,400 respondents shared how poor air quality—especially from wildfires—has affected their daily lives: 🔹 98% of respondents said poor air quality worsens their asthma 🔹 73% said poor air quality has directly caused their asthma to flare up severely 'It's not just about breathing issues—it's about your whole quality of life,' said Grace Pyatt, a nurse and professional beach volleyball player from Niagara, Ontario. 'I trained outdoors during wildfire season, and the smoke made everything harder. I was exhausted, constantly needing my rescue inhaler, and couldn't function outside of training. It took a toll on my mental and physical health—and it made me realize how serious wildfire smoke is for people with asthma.' The survey also revealed the mental health toll wildfire smoke takes on people with asthma: 🔹 85% reported a decline in their mental health during times of poor air quality 🔹 71% experienced anxiety that wildfire smoke could cause their asthma to flare up 'During wildfire season, I'm constantly on edge—worried that my asthma will flare up or that I'll have a serious attack. It's a terrifying feeling knowing it can be life-threatening,' said Charly Jarrett, a digital consultant from the West Kootenays, British Columbia. 'There's also a real sense of isolation. While others are outside enjoying the summer, I often have to stay indoors just to stay safe. It can feel incredibly lonely.' To help individuals protect themselves this summer, Asthma Canada has developed these essential tips: 🔷 7 Practical Steps to Manage Your Asthma During Wildfire Season 1. Stay informed: Keep track of local air quality updates and wildfire information from reliable sources like Environment Canada, The Weather Network, and the Government of Canada. 2. Have an updated Asthma Action Plan: Your plan should outline steps to take in case of worsening asthma symptoms or emergencies. Download your plan now. 3. Limit outdoor activities: Stay indoors as much as possible. Avoid physical exertion and exercise outdoors during peak pollution periods. If going outside is necessary: 🔹Wear a well-fitted N95 respirator mask to help protect against smoke particles. These can be purchased at pharmacies and online. 🔹Keep your reliever (usually blue) inhaler with you at all times in case asthma symptoms arise. 🔹When driving, keep your windows and vents closed and use air conditioning only in the 'recirculate' setting. 4. Use air purifiers and filters in your home: Use high-efficiency particulate air (HEPA) purifiers and keep windows and doors closed to prevent smoke infiltration. If using an air conditioner, choose the recirculation setting so outside air is not transferred inside. Avoid activities that contribute to indoor air pollution, such as smoking or using strong chemicals. 5. Take your medications as prescribed: Make sure you have necessary medications and supplies readily available and follow your prescribed asthma medication regimen, including both preventive and rescue medications. Consult your healthcare provider if you need to adjust your medication plan during episodes of poor air quality. 6. Stay hydrated: Drink plenty of fluids to keep your airways hydrated. This can help reduce symptoms and keep mucus thin, making it easier to cough up if necessary. 7. Watch Asthma Canada's Webinar: How Air Quality and Wildfires Affect Your Health In this informative session, respiratory experts Dr. Emily Brigham (Associate Professor, UBC) and Dr. Chris Carlsten (Director, Centre for Lung Health) explain how wildfire smoke and poor air quality affect your lungs—and share practical tips to help you stay healthy during wildfire season. 'Wildfire smoke can make asthma symptoms much worse, and for some, it can be life-threatening,' said Jeffrey Beach, President & CEO of Asthma Canada. 'If you have questions or concerns about managing your asthma—especially during wildfire season—we encourage you to reach out to our Asthma & Allergy HelpLine at 1-866-787-4050 or [email protected]. Our Certified Respiratory Educators are here to help you breathe easier and stay safe.' About Asthma Canada: Asthma Canada is the only national healthcare charity solely dedicated to improving the quality of life for people living with asthma and respiratory allergies. For more than 50 years, Asthma Canada has proudly served as the national voice for people in Canada living with asthma. Our mission is to help people living with asthma lead healthy lives through education, advocacy, and research. Our vision is a future without asthma. For more information, please visit About Asthma in Canada: 🔹Over 4.6 million people are living with asthma in Canada 🔹Including over 900,000 children under 19 and over 800,000 adults over 65 🔹As many as 465,000 people living with asthma in Canada have severe asthma 🔹Including over 45,000 children under 19 🔹Asthma is Canada's third most chronic disease 🔹Over 300 families lose a loved one to asthma each year 🔹$4.2 billion is the expected cost of asthma to the Canadian economy by 2030 annually 🔹317 people are diagnosed with asthma every day in Canada 🔹80,000 visits are made to the emergency room each year because of asthma attacks 🔹Some people in Canada are hit harder by asthma; it is 40% more prevalent among First Nations, Inuit and Metis communities than the general population in Canada. Pauric Keegan Asthma Canada +1 866-787-4050 [email protected] Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
11 hours ago
- Associated Press
Summit Spine Continues Expansion into North Carolina, Partners with Dr. Louis Torres
'We are thrilled to welcome Dr. Louis Torres to our team as we continue to enhance access to advanced pain care for the Fayetteville community.'— Dr. Amit Patel, CEO and Founder of Summit Spine & Joint Centers FAYETTEVILLE, NC, UNITED STATES, June 12, 2025 / / -- Summit Spine & Joint Centers, a leading multi-location provider of minimally invasive spine care, proudly announces the appointment of Dr. Louis Torres as the newest physician leader. Dr. Torres will support Summit's growing North Carolina operations – which operate under the Integrated Pain Solutions brand. Dr. Torres' arrival represents a strategic milestone in the organization's continued commitment to delivering best-in-class musculoskeletal (MSK) solutions to the Fayetteville region. With an established presence spanning 30 locations in Georgia, 11 in North Carolina, one in Tennessee, and two in South Carolina, Summit Spine & Joint Centers has earned widespread recognition for its excellence in pain management and compassionate patient care. The addition of Dr. Torres strengthens the Company's dedication to expanding access to high-quality, patient-focused care for individuals suffering from chronic pain across the Southeast. Specializing in the diagnosis and treatment of complex conditions—including neck and back pain, sciatica, herniated discs, headaches, pelvic and musculoskeletal pain, and neuropathic disorders—Summit Spine leverages state-of-the-art technologies to deliver precision-based care tailored to each patient's needs. 'We are thrilled to welcome Dr. Louis Torres to our team as we continue to enhance access to advanced pain care for the Fayetteville community,' said Dr. Amit Patel, CEO and Founder of Summit Spine & Joint Centers. 'Our team of highly skilled physicians, nurses, and support staff are united by a shared mission: to improve lives by relieving pain and restoring function through innovative, minimally invasive treatments.' Dr. Torres, a Fayetteville-based physician with strong ties to the region, shared his enthusiasm for the partnership: 'I'm honored to expand access to advanced pain care in a community that means so much to me. Summit's focus on cutting-edge technology and its collaborative, patient-centered approach ensures that each patient receives the highest level of comprehensive and compassionate care.' Summit Spine & Joint Centers operates 17 ASCs and 44 clinics across four (4) states, with Georgia locations in Athens, Augusta, Braselton, Buford, Canton, Carrollton, Cartersville, Columbus, Commerce, Conyers, Covington, Cumming, Dalton, Decatur, East Cobb, Gainesville, Jasper, Johns Creek/Norcross, Lawrenceville, Lithia Springs, Newnan, Ringgold/Ft. Oglethorpe, Rome, Roswell, Savannah, Snellville, Stockbridge, Stonecrest/Lithonia, Winder, and Woodstock; North Carolina clinics in Asheboro, Beaufort, Fayetteville, Jacksonville, Laurinburg (2), Rockingham, Southern Pines, Wadesboro, Whiteville, and Wilmington; clinics South Carolina locations in Greenville and Spartanburg; and a clinic in Chattanooga, Tennessee. For more information call (864) 383-0669 or visit Samantha Montague Summit Spine & Joint Centers +1 404-784-5318 email us here Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
2 days ago
- Associated Press
BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS)
NORTH BRUNSWICK, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for acute and chronic inflammatory diseases, announces that it will conduct a Phase 2 study of rhu-pGSN for decompression sickness (DCS) under a contract awarded by the U.S. Navy's Office of Naval Research to the University of Maryland School of Medicine (UMSOM). This work is the culmination of an extended collaboration with Dr. Stephen Thom, Professor of Emergency Medicine at UMSOM. The Company's portfolio is built around gelsolin, a highly conserved and critical immune regulatory protein which rebalances dysfunctional inflammation without suppressing immune function. Phase 2 Clinical Trial of Rhu-pGSN The study, 'Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers,' NCT06216366 is being conducted under a contract with the Office of Naval Research with the University of Maryland. It will investigate the use of rhu-pGSN as a pre- or post-exposure intervention in healthy trained SCUBA divers exposed to controlled hyperbaric conditions. The study is designed to assess the impact of rhu-pGSN on key inflammatory responses and microparticle production associated with decompression. Decompression sickness occurs when inert gas bubbles form in the bloodstream and tissues due to rapid pressure changes, triggering an inflammatory cascade. Previous studies have shown that individuals with DCS exhibit depleted levels of plasma gelsolin and elevated levels of microparticles that contain inflammatory cytokines. In animal models, supplementation with rhu-pGSN both prevented and mitigated DCS-related complications. This randomized, double-blind, placebo-controlled study will enroll healthy trained SCUBA divers at a single site and expose them to a standardized hyperbaric protocol (30 meters of seawater for 35 minutes). Participants will be randomized into three groups to receive either pre-exposure or post-exposure rhu-pGSN, or placebo. The study will assess a broad range of outcomes including plasma gelsolin levels, inflammatory markers like IL-1β, gas bubble formation, and well-being metrics. Dr. Thom states, 'If successful, this study could transform the way we manage decompression sickness by providing a portable, field-deployable treatment option. Reducing our reliance on hyperbaric chambers would greatly expand our ability to treat DCS in remote or operational environments, improving outcomes and readiness, a key goal for the Navy.' BioAegis and University of Maryland are co-applicants on a patent filing listing Dr. Thom as an inventor. Gelsolin: A Multitasking Protein for Complex Inflammatory Conditions Rhu-pGSN holds immense promise as a therapeutic intervention for serious acute and chronic conditions due to its multifaceted mechanism of action. In critical illness, gelsolin levels collapse, causing adverse outcomes. Supplementing gelsolin addresses this deficit directly, restoring immune balance while preserving host defense and rhu-pGSN has been shown in animal studies to: Supplementation with the recombinant gelsolin protein holds promise to address the overzealous inflammatory response associated many inflammatory diseases without suppressing immune function. About BioAegis BioAegis Therapeutics Inc. is a NJ-based clinical-stage private company whose mission is to capitalize on a key regulatory component of the body's immune system, plasma gelsolin, to prevent adverse outcomes in diseases driven by inflammation. BioAegis has the exclusive license to broad, worldwide intellectual property through Harvard-Brigham and Women's Hospital. It holds over 40 patents issued for coverage of inflammatory disease, infection, renal failure, neurologic disease, and frailty. BioAegis will also have U.S. biologics exclusivity and has recently filed new IP in areas of unmet need. BioAegis' lead product, rhu-pGSN, is currently being studied in a 600-patient global Phase 2 trial for patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS). This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50123C00067. NCT05947955 Investor Inquiries: Steven Cordovano 203-952-6373 [email protected] Media Inquiries: Christine Lagana [email protected]
